These findings exposed an opportunity to treat these cancers through blockade of programmed cell death protein 1 (PD1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA4), immune checkpoints that silence CTL response. Here, PDCD1 is linked to cancer.